Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Celecoxib 200 mg BID Clear all

Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions: DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod; Biological · Drug
Lead sponsor: David Bartlett; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Colorectal Cancer, Pain
Interventions: Capecitabine, Celecoxib, Radiation Therapy, Placebo; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more

Conditions: Osteoarthritis
Interventions: TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo; Drug · Other
Lead sponsor: Mika Pharma GmbH; Industry
Eligibility: 40 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 43
States / cities: Huntsville, Alabama • Mobile, Alabama • Mesa, Arizona + 35 more

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Relapsed Multiple Myeloma
Interventions: ATRA, Celecoxib, Itraconazole; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Smoking, Prevention
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 74 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Celecoxib, Naproxen, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Shoulder Arthropathy, Shoulder Pain
Interventions: Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
Interventions: Famotidine, Celecoxib, Placebo; Drug · Other
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Opioid Use Disorder
Interventions: Buprenorphine, Oxycodone; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Low Back Pain
Interventions: celecoxib, tramadol HCL; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more

Conditions: Back Pain
Interventions: Tramadol Hydrochloride 50mg, Celebrex 200mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 754 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 53
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more

Conditions: Lung Cancer
Interventions: celecoxib, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 44
States / cities: Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more

Conditions: Breast Cancer
Interventions: Exemestane, Celecoxib, Correlative studies; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bowel Diseases, Inflammatory
Interventions: Celecoxib, Placebo, Ibuprofen plus Omeprazole; Drug · Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 12
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more

Conditions: Brain and Central Nervous System Tumors, Glioblastoma Multiforme
Interventions: Celecoxib, Isotretinoin, Temozolomide, Thalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 12
States / cities: Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more

Conditions: Osteoarthritis, Pain
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Aurora, Colorado • Englewood, Colorado • Chicago, Illinois + 3 more

Conditions: Osteoarthritis, Knee
Interventions: Celecoxib, Naproxen, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 51
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 41 more

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug · Other
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteoarthritis
Interventions: TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo; Drug · Other
Lead sponsor: Mika Pharma GmbH; Industry
Eligibility: 40 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 49
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 42 more

Conditions: Obesity
Interventions: Celebrex; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Tonsillitis
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Arthritis, Rheumatoid
Interventions: celecoxib, Ibuprofen, Naproxen; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 871
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more

Search by objective public record fields.

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

ATRA, Celecoxib, and Itraconazole as Maintenance

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

Variability in Response to Non-steroidal Anti-inflammatory Drugs

Opioid-Free Pain Protocol After Shoulder Arthroplasty

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

Examining Analgesic Synergy and Efficacy in Trauma Care

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Celebrex Total Knee Arthroplasty Study

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

Celecoxib as a Post-tonsillectomy Pain Medication

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen